Screening women for oral contraception: Can family history identify inherited thrombophilias?

Obstetrics and Gynecology

Volumn 120, Issue 4, 2012, Pages 889-895

  Grimes, David A ^a   Stuart, Gretchen S ^a   Levi, Erika E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

BIBLIOGRAPHIC DATABASE; COMPUTER SYSTEM; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG SAFETY; FAMILY HISTORY; FEMALE; HUMAN; INHERITANCE; INTERNAL VALIDITY; LABORATORY TEST; MEDICAL DOCUMENTATION; MEDICAL INFORMATION; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; ORAL CONTRACEPTION; PATIENT REFERRAL; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; MEDICAL HISTORY TAKING; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 84866936357     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3182699a2b     Document Type: Review

References (47)

1. Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 2006;73:166-78.
2. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep 2010;59(No. RR-4):1-86.
3. World Health Organization. Medical eligibility criteria for contraceptive use. 4th ed. Geneva (Switzerland): World Health Organization; 2010.
4. Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999;72:646-51.
5. Kalev M, Day T, Van de Water N, Ockelford P. Screening for a prothrombotic diathesis in patients attending family planning clinics. N Z Med J 1999;112:358-61.
6. Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: Should we screen oral contraceptive users and pregnant women? BMJ 1996;313:1127-30.
7. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-54.
8. Vandenbroucke JP, van der MeF, Helmerhorst FM, Rosendaal FR. Family history and risk of venous thromboembolism with oral contraception. Family history is important tool. BMJ 2001;323:752.
9. Hubacher D, Grimes D, Lara-Ricalde R, de la Jara J, Garcia-Luna A. The limited clinical usefulness of taking a history in the evaluation of women with tubal factor infertility. Fertil Steril 2004;81:6-10.
10. Greenhalgh T, Peacock R. Effectiveness and efficiency of search methods in systematic reviews of complex evidence: Audit of primary sources. BMJ 2005;331:1064-5.
11. Amberger N, Masuhr F, Valdueza JM, Vetter B, Weih M. A negative personal and family history for venous thrombotic events is not sufficient to exclude thrombophilia in patients with cerebral venous thrombosis. Eur J Neurol 2004;11:555-8.
12. Aznar J, Mira Y, Vaya A, Ferrando F, Villa P. Is family history sufficient to identify women with risk of venous thromboembolism before commencing the contraceptive pill? Clin Appl Thromb Hemost 2002;8:139-41.
13. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009;169:610-5.
14. Cosmi B, Legnani C, Bernardi F, Coccheri S, Palareti G. Value of family history in identifying women at risk of venous thromboembolism during oral contraception: Observational study. BMJ 2001;322:1024-5.
15. Cosmi B, Legnani C, Bernardi F, Coccheri S, Palareti G. Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. Arch Intern Med 2003;163:1105-9.
16. Dietrich JE, Hertweck SP, Perlman SE. Efficacy of family history in determining thrombophilia risk. J Pediatr Adolesc Gynecol 2007;20:221-4.
17. Eggert-Kruse W, Ziegler A, Horlbeck S, Strowitzki T. Medical history screening for thrombophilic risk: Is this adequate? Fertil Steril 2011;95:1917-21.
18. Horton AL, Momirova V, Dizon-Townson D, Wenstrom K, Wendel G, Samuels P, et al. Family history of venous thromboembolism and identifying factor V Leiden carriers during pregnancy. Obstet Gynecol 2010;115:521-5.
19. Schambeck CM, Schwender S, Haubitz I, Geisen UE, Grossmann RE, Keller F. Selective screening for the Factor V Leiden mutation: Is it advisable prior to the prescription of oral contraceptives? Thromb Haemost 1997;78:1480-3.
20. van Sluis GL, Sohne M, El Kheir DY, Tanck MW, Gerdes VE, Buller HR. Family history and inherited thrombophilia. J Thromb Haemost 2006;4:2182-7.
21. Caprini JA, Goldshteyn S, Glase CJ, Hathaway K. Thrombophilia testing in patients with venous thrombosis. Eur J Vasc Endovasc Surg 2005;30:550-5.
22. DeSancho MT, Dorff T, Rand JH. Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy. Blood Coagul Fibrinolysis 2010;21:534-8.
23. Noboa S, Le Gal G, Lacut K, Mercier B, Leroyer C, Nowak E, et al. Family history as a risk factor for venous thromboembolism. Thromb Res 2008;122:624-9.
24. Ruud E, Holmstrom H, Brosstad F, Wesenberg F. Diagnostic value of family histories of thrombosis to identify children with thrombophilia. Pediatr Hematol Oncol 2005;22:453-62.
25. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003;49:1-6.
26. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002;359:881-4.
27. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 1996;143:1257-65.
28. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-12.
29. Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet 2005;365:1500-5.
30. Grimes DA, Peipert JF. Electronic fetal monitoring as a public health screening program: The arithmetic of failure. Obstet Gynecol 2010;116:1397-400.
31. Martin DH, Cammarata C, Van Der Pol B, Jones RB, Quinn TC, Gaydos CA, et al. Multicenter evaluation of AMPLICOR and automated COBAS AMPLICOR CT/NG tests for Neisseria gonorrhoeae. J Clin Microbiol 2000;38:3544-9.
32. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994;271:703-7.
33. Eikelboom JW, Weitz JI. Importance of family history as a risk factor for venous thromboembolism. Circulation 2011;124: 996-7.
34. Simonis G, Schmeisser A, Strasser RH. Thrombembolism in a young woman with previously unrecognized hereditary hemophilia: Obtaining a family history is still strongly recommended before starting oral contraceptives [in German]. Dtsch Med Wochenschr 2007;132:2327-9.
35. Briet E, van der Meer FJ, Rosendaal FR, Houwing-Duistermaat JJ, van Houwelingen HC. The family history and inherited thrombophilia. Br J Haematol 1994;87:348-52.
36. Wilson BJ, Qureshi N, Santaguida P, Little J, Carroll JC, Allanson J, et al. Systematic review: Family history in risk assessment for common diseases. Ann Intern Med 2009;151: 878-85.
37. Wilson B, Qureshi N, Little J, Santaguida P, Carroll J, Allanson J, et al. Clinical utility of cancer family history collection in primary care. Evid Rep Technol Assess (Full Rep) 2009;179: 1-94.
38. Qureshi N, Wilson B, Santaguida P, Little J, Carroll J, Allanson J, et al. Family history and improving health. Evid Rep Technol Assess (Full Rep) 2009;186:1-135.
39. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet 2002;359:248-52.
40. Schwingl PJ, Ory HW, Visness CM. Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States. Am J Obstet Gynecol 1999;180: 241-9.
41. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: Cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 2010;340:c927.
42. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: Cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007;335:651.
43. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: What it is and what it isn't. BMJ 1996;312:71-2.
44. Law M. Screening without evidence of efficacy. BMJ 2004;328: 301-2.
45. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. The Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD001292. DOI: 10.1002/14651858.CD001292.pub2.
46. Palareti G, Legnani C, Frascaro M, Flamigni C, Gammi L, Gola G, et al. Screening for activated protein C resistance before oral contraceptive treatment: A pilot study. Contraception 1999;59:293-9.
47. Dizon-Townson D, Miller C, Sibai B, Spong CY, Thom E, Wendel G Jr, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005;106:517-24.